KOS PHARMACEUTICALS
Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The companyโs principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos๏ฟฝ... ๏ฟฝ๏ฟฝ strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The company currently markets Niaspan, Advicor, Azmacort, Cardizem LA, Teveten and Teveten HCT. Kos has a strong and growing research and development pipeline including proprietary drug delivery technologies in solid-dose, inhalation and aerosol metered-dose device administration to help fuel sustained, organic sales growth into the future.
KOS PHARMACEUTICALS
Social Links:
Industry:
Health Care Medical Pharmaceutical
Founded:
1988-01-01
Address:
Cranbury, New Jersey, United States
Country:
United States
Total Employee:
1001+
Status:
Active
Total Funding:
0
Similar Organizations
Acuity Pharmaceuticals
Acuity Pharmaceuticals product-focused ophthalmic pharmaceutical company applying its proprietary technology to the treatment.
Eleison Pharmaceuticals
Eleison Pharmaceuticals acquires, develops, and commercializes clinical stage drug candidates for "orphan" cancers.
Investors List
Bill Pruitt
Bill Pruitt investment in Seed Round - KOS Pharmaceuticals
More informations about "KOS Pharmaceuticals"
Abbott to acquire Kos Pharmaceuticals for $3.7 billion
Abbott and Kos Pharmaceuticals Inc. on November 6 announced a definitive agreement for Abbott to acquire Kos for $78 per share in cash, for a total transaction value of $3.7 billion, net โฆSee details»
Kos Pharmaceuticals Company Profile 2024: Valuation, Investors ...
Information on acquisition, funding, investors, and executives for Kos Pharmaceuticals. Use the PitchBook Platform to explore the full profile.See details»
Kos Pharmaceuticals, Inc. - SEC.gov
Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products โฆSee details»
Kos Pharmaceuticals Company Profile | Management and
Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products โฆSee details»
KOS Pharmaceuticals Inc - Company Profile and News
Company profile page for KOS Pharmaceuticals Inc including stock price, company news, executives, board members, and contact informationSee details»
KOS Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for KOS Pharmaceuticals, Inc. of Cranbury, NJ. Get the latest business insights from Dun & Bradstreet.See details»
KOS Pharmaceuticals - Funding, Financials, Valuation & Investors
Jan 1, 2004 KOS Pharmaceuticals is a pharmaceutical company that manufactures prescription products.See details»
Organization | Kos Pharmaceuticals
Kos Pharmaceuticals Report issue For profit Phase 4 Founded: Cranbury NJ United States (1988) Status: Acquired by Abbott (2006) Organization Overview First Clinical Trial 2000 โฆSee details»
Kos Pharmaceuticals Profile: Summary โข OpenSecrets
Kos Pharmaceuticals organization profile. Contributions in the 2022 cycle: $100. Lobbying in 2022: $0. Outside Spending in the 2022 cycle: $0.See details»
Kos Pharmaceuticals, Inc - Encyclopedia.com
Kos Pharmaceuticals, Inc. specializes in the development of proprietary pharmaceutical products for the treatment of cardiovascular and respiratory disease through the reformulation of โฆSee details»
KOS PHARMACEUTICALS, INC. - SEC.gov
A predecessor corporation to the Company was formed in July 1988 under the name of Kos Pharmaceuticals, Inc. principally to conduct research and development on new formulations of โฆSee details»
Abbott Completes Kos Acquisition | Quality Digest
Abbott Laboratories has completed its acquisition of Kos Pharmaceuticals Inc., which specializes in treatments for cardiovascular, metabolic and respiratory diseases, and is now a wholly โฆSee details»
Kos Pharmaceuticals, Inc. - SEC.gov
Kos Pharmaceuticals, Inc. ( Kos or the Company ) is a fully-integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary prescription โฆSee details»
Abbott To Buy Kos Pharmaceuticals for $3.7 Billion - PharmTech
Nov 9, 2006 Abbott Park, IL (Nov. 6)-Abbott Laboratories agreed to acquire the specialty pharmaceutical company Kos Pharmaceuticals, Inc. for $3.7 billion.See details»
Kos Pharmaceuticals to Pay More Than $41 Million to Resolve โฆ
Dec 7, 2010 Kos Pharmaceuticals, a subsidiary of Abbott Laboratories, has agreed to pay more than $41 million to resolve criminal and civil liability arising from conduct relating to its drugs โฆSee details»
KOS PHARMACEUTICALS, INC. FORM 10-K - SEC.gov
Kos Pharmaceuticals, Inc. ( Kos or the Company ) is a fully-integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary prescription โฆSee details»
Abbott to buy drug rival for $3.7 billion - NBC News
Nov 6, 2006 Abbott Laboratories Inc. said Monday it will acquire Kos Pharmaceuticals Inc. for $3.7 billion to boost its presence in the lucrative cholesterol-treatment market.See details»
Kos Pharmaceuticals, Inc. - SEC.gov
Market its products directly through the Company s sales forces, which Kos may supplement with one or more contract sales organizations or other partners and through co-promotion and โฆSee details»
Kos Pharmaceuticals gets $50 million boost - The Pharma Letter
Dec 20, 1999 Kos Pharmaceuticals says that it has secured an additional $50 millionstandby credit facility from Michael Jaharis, its chairman and main shareholder, which will enable the โฆSee details»